

The International Federation of Head and Neck Oncologic Societies

Current Concepts in Head and Neck Surgery and Oncology 2017



www.ifhnos.net




The International Federation of Head and Neck Oncologic Societies

Current Concepts in Head and Neck Surgery and Oncology 2017

SCCHN: Multimodal Therapy

Merrill S. Kies

RTOG 0522 Phase III: CB-XRT +/- C225 Chemoradiotherapy for Locally Advanced Disease





EGFR-Based Bioradiotherapy with Panitumumab (P)

Concert 1	<u>N</u>	2-yr LRC %
CT – RT	63	68
CT - RT + P	87	61

Concert 2

CT - RT 61 61 P - RT 90 51



MACH-NC Update Concomitant vs Induction CT

- Concomitant superior in LRC and event-free survival; trend for OS (p=0.15)
- Induction superior for reduction in distant failure.
 - Induction: HR 0.73 (0.61-0.88), p=0.001
 - Concomitant: HR 0.88 (0.77-1.00), p=0.04
- Authors suggest the potential for sequencing the two approaches, with concern re adverse impact on compliance/ toxicities




TAX 323 and TAX 324: Summary

- Response rates are higher with TPF compared to PF
- Induction TPF improves survival compared to PF, possibly due to increased LRC
- Rate of distant failure is low
- There was no comparison with accepted CT-



DECIDE Phase III Trial: TPF Followed by ChemoRT Versus Concurrent ChemoRT




TPF: docetaxel + cisplatin + 5-FU q 3 wk x 2

DFHX: docetaxel + hydroxyurea + FU + hyperfractionated RT




Overall Survival by Treatment Arm Primary Endpoint





Overall Survival by Nodal Stage


N2A/N2B (n=139) N2C/N3 (n=96)



Blue: IC, Red: CRT




The PARADIGM Study: Sequential Therapy vs Chemoradiotherapy A Phase III Study of TPF/C-XRT vs P-ACBXRT





PI: Robert Haddad

PARADIGM: Progression Free Survival



Is There Still a Role for Induction Chemotherapy for Head and Neck Cancer?

Adam S. Garden, *The University of Texas MD Anderson Cancer Center, Houston, TX*J Clin Oncol 23(6):1059-60, 2015. Editorial




Phase II Study of TPF Followed by Cisplatin/5-FU/XRT

Stage III/IV M0 HNSCC

Unresectable disease


PS 0-1

N=103 patients





Primary endpoint: radiologic CR after chemoXRT





T P F

Q 3 weeks x 3 cycles

no induction

PF RT - 70Gy

CCCCCCC

RT - 70Gy

A2

PF RT - 70Gy

CCCCCCC

RT - 70Gy

B2

B1

Primary endpoints:

- 1) 3y OS Induction vs no induction: A1 + A2 vs B1 + B2
- 2) 2) G3-4 in field toxicity: A1 + B1 vs A2 + B2

Compliance with Concomitant Treatments


	TPF + concomitant n=185	Concomitant n= 199	p value
PF 2 cy/cetuximab 7 wks - no modifications	86% 56%	88% 59%	0.772
RT completion - no modifications	93% 61.5%	93% 64.5%	0.820
Median RT dose, Gy (range)	70 (8-73)	70 (18-70)	0.199
Median RT duration, weeks (range)	7.3 (1-13)	7.4 (3-11)	0.674
Pts with RT interruption > 3 consecutive days (%)	51 (27.5%)	59 (30%)	0.607
Death from any cause within 30 days after treatments	6 (3%)	7 (3.5.%)	0.772

Presented by: MG Ghi, MD

PRESENTED AT:



Progression Free Survival




Presented by: MG Ghi, MD

en and Neck Oncologie

PRESENTED AT:



Overall Survival



Presented by: MG Ghi, MD

en and Neck Oncologie

PRESENTED AT:



Induction CT Trial Outcomes

			<u> </u>	<u>/r % </u>
		<u>N</u>	<u>PFS</u>	<u>os</u>
	ICT	70	67	73
Paradigm	CT – RT	75	69	78
			4-	
DeCIDE <	ICT	142	67	75
DECIDE	CT - RT	138	60	74
Ghi, et al	ICT	199	47	58
ormy see di	CT - RT	185	37	46



HPV-positive and negative cancers

HPV-related cancers

- Caused by HPV
 - HPV 16 is high-risk subtype
 - Driven by viral oncogenes
- Concentrated in oropharynx
- E6 and E7 oncogenes
- Young, favorable health
- Cured in 80%


SCC related to substance abuse

- Caused by toxic exposures
 - Tobacco and alcohol
- Throughout HN mucosa
- P53 mutations
- "Poor" prognosis, comorbidities
- Second primary cancers



50-y/o man, HPV+, mostly cystic nodes,





2017

59-y/o man, HPV+, cystic nodes, occult primary





Integrating Accelerated Fractionation & Cisplatin Phase III Trial RTOG 0129, PI: K. Ang

R

O

M

Z

Stage III & IV SCC of:

- Oral cavity
- Oropharynx
- Larynx
- Hypopharynx

Stratify:

- Lx vs Non-Lx
- N0 vs N+
- KPS 60-80 VS 90-100


A → 1. SFX: 70 Gy/35 F/7 W + CDDP: 100 mg/m² (d 1, 22, 43)

→ 2. AFX-CB: 72 Gy/42 F/6 W + CDDP: 100 mg/m² (d 1, 22)

Accrued 743 patients
Collected 596 tumor specimens


Oropharyngeal Cancer Enrolled: 433 - Specimens: 317

Excluded T1-2N1






E1308: Reduced Dose IMRT for HPV+ Stage III/IV OPSCC Patients Achieving cCR to ICT






Progression Free and Overall Survival in Clinical CRs





PFS and OS in Favorable Cohort





Diagnostic biopsy, staging, and functional awareness assay (N = 47)

MDA 03-0919

Weekly chemotherapy
Cetuximab 400 mg/m² wk 1
250 mg/m² wks 2-6
Paclitaxel 135 mg/m² wks 1-6
Carboplatin (AUC 2) wks 1-6

Assessment of response

Assignment based on site/staging at diagnosis

Radiation (N = 23)

Chemo RT (N = 23)


Surgery (N = 1)



Overall Survival for 2003-0919 (H/N SPORE)

5-year survival

- No new LR recurrence
- 1 new SPM (spindle cell scalp)
- Overall survival: 89%





n=42 long-term survivors Most OP survivors (39) Chronic dysphagia rare Hutcheson K et al, Head and Neck 2013

Functional Outcomes

5-year

2017

Diet		
NPO	1 (2%)	1 (3%)
Tube + PO	1 (2%)	0 (0%)
Liquid only	1 (2%)	1 (3%)
Soft	5 (12%)	5 (13%)
Regular/full	34 (81%)	32 (82%)
Feeding-tube	2 (5%)	1 (3%)
Laryngectomy	1 (2%)	1 (3%)
Tracheostomy	0 (0%)	0 (0%)
Pneumonia	2 (5%)	1 (3%)
Stricture	0 (0%)	0 (0%)
Chronic dysphagia*	3 (7%)	1 (3%)
Total	42	39
*composite endpoint of chronic dysphagia defined by chronic aspiration or stricture per MBS and/or permanent gastrostomy dependence		

^{0(%)} (3%)(13%)(82%)(3%)(3%)0(%)

All sites

(n=42)

OroPh

(n=39)

MDA 2009-0885 Schema

Diagnosis & Staging + Biopsies

After stratification for HPV status, positive patients with N2b/c/3 disease are eligible and randomized to PCC v TPF-C

Response Assessment + Biopsies

Patients with staging at diagnosis T 0-3



Patients with staging, at diagnosis T4 or unresectable N+

Radiation Therapy

Chemoradiotherapy




MDA 2009-0885 / Biomarker Correlates

- Immunoprofiling CD3, DC4, LD8, RO, FOXp3, CD68, LD 113, PD-L1
- Blood flow cytometry for T cells
- Tumor mutation panel



Study Population




and Neck Onculous

Primary objective: Estimated 2-year Progression free survival rate

	All patients % (CI)	PCC % (CI)	C-TPF % (CI)
Overall		89 (81, 99)	80 (68, 93)
Low risk	89 (81, 97)	95 (88, 100)	82 (69, 97)
I/H risk	74 (58, 95)	72 (49, 100)	75 (53, 100)



Primary objective: Progression free survival by risk group





and Neck Onculous

Estimated 2 year Progression free survival: subgroup analysis


	PCC % (CI)	C-TPF % (CI)
HPV-positive/never smokers	100 (100, 100)	86 (70, 100)
HPV-positive/<=10 pack years	100 (100, 100)	88 (67, 100)
HPV-positive/>10 pack years	87 (71, 100)	65 (44, 97)
HPV-negative	76 (55, 100)	83 (58, 100)
N2c-N3	83 (67, 100)	82 (67, 100)
N0-N2b	93 (85, 100)	78 (62, 98)



Trial Design (MDA 2013-0179)

Stage I (biomarker discovery/validation)

adaptive randomization based on pathologic response



Stage II (personalized biomarker-driven therapy)






adaptive randomization based on stage 1 markers

THE SEQUENTIAL CT AND RT PLATFORM FOR LOCALLY ADVANCED SCCHN

Systemic Rx \rightarrow RT (+/- CT) \rightarrow S



Basis for Immune therapy – Immune Escape



- Expression of PD-L1 on
 - a) tumor cells &
 - b) macrophages

can suppress immune surveillance.

- In mouse models antibodies blocking PD-1 / PD-L1 interaction lead to tumor rejection
- Clinical prognosis
 correlates with
 presence of TILs
 and PD-L1
 expression in
 multiple cancers.

CT - Observations

- Individualization of therapy continues to be based on site, stage, HPV status, PS, and tobacco consumption history
- CT RT remains the fundamental consideration for nonsurgical rx of locally advanced ds
- Pts with bulky N2b/c, N3, N level 4 are candidates for systemic rx and study
- Modification of combined treatment regimens in HPV+ ds is under investigation
- Efficacy relates to the entire treatment sequence
- Induction therapy is an investigational vehicle for the study of clinical and molecular endpoints



Old Texas Longhorn





Twin Creek Ranch of Cat Spring, Texas